Skip to Content

New Data on Oral Decitabine in MDS: Real-Life Analysis and Outcomes from ASH2023

In this MEDtalk, Dr. Amer Zeidan, Associate Professor of Medicine at Yale University, shares data on the effectiveness of oral decitabine (DEC-C) for Myelodysplastic Syndrome (MDS) in a real-life analysis. In August 2020, DEC-C was approved in the U.S. for high-risk MDS patients. The study focused on treatment adherence because fewer than half of eligible patients persist with the treatment long enough for it to be effective. Therefore, investigating whether an oral alternative can lead to better outcomes is important, and this retrospective data set suggests that oral treatment does indeed lead to better outcomes. Watch the MEDtalk and find out more.

Amer Zeidan

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top